KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T.

Fumihiro Tanaka, Yasutaka Watanabe, Shunichi Sugawara, Jiro Okami, Satoshi Muto, Morihito Okada, Yoshitsugu Horio, Masahiro Tsuboi, Yuki Sato, Kazuya Takamochi, Hidehito Horinouchi, Yuichi Tambo, Masahiro Seike, Kyoichi Okishio, Cinthya Coronado Erdmann, Padma Sathyanarayana, Stephanie Meadows-Shropshire, Hiroyuki Ito

Cancer Sci 117(3) 759-768

PMID41431434
PMCIDPMC12951114
DOI10.1111/cas.70300
发表日期2025-12-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the randomized phase III CheckMate 77T study, perioperative nivolumab showed statistically significant and clinically meaningful improvement in event-free survival (EFS) vs. placebo in patients with resectable, non-metastatic non-small cell lung cancer (NSCLC). Here, we report efficacy and safety outcomes in the Japanese subpopulation. Adults with resectable stage IIA-IIIB NSCLC were randomized 1:1 to neoadjuvant nivolumab plus chemotherapy or chemotherapy plus placebo every 3 weeks for ≤ 4 cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for ≤ 13 cycles. Assessments included EFS (primary endpoint), pathological complete response (pCR), major pathological response (MPR), and safety. A total of 68 Japanese patients were randomized to perioperative nivolumab (n = 40) or placebo (n = 28). At 24.9 months' median follow-up, median EFS was not reached (NR; 95% CI: 21.4-NR) with perioperative nivolumab vs. 12.1 (95% CI: 8.1-NR) months with placebo (hazard ratio, 0.46 [95% CI: 0.22-0.95]); 18-month EFS rates were 76.6% vs. 42.9%, respectively. The pCR rate (95% CI) was 42.5% (27.0%-59.1%) with perioperative nivolumab vs. 0% (0%-12.3%) with placebo (odds ratio [OR], not available); MPR rate (95% CI) was 52.5% (36.1%-68.5%) vs. 7.1% (0.9%-23.5%), respectively (OR, 14.37; 95% CI: 3.00-68.82). Grade 3-4 treatment-related and surgery-related adverse events with perioperative nivolumab vs. placebo occurred in 55.0% vs. 39.3% and 16.7% vs. 19.2% of patients. Consistent with the global population, perioperative nivolumab improved EFS, pCR, and MPR vs. placebo in the Japanese subpopulation, with no new safety signals reported, supporting its use in Japanese patients with resectable NSCLC. Trial Registration: ClinicalTrials.gov identifier, NCT04025879.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

FIGURE 2

FIGURE 2 EFS per BICR in Japanese patients. BICR, blinded independent central review; CI, confidence interval; EFS, event‐free survival; HR, hazard ratio; mo, months; NR, not reached. 95% CIs for perioperative nivolumab and placebo, respectively: a 66%–91% and 31%–67%; b 60%–87% and 25%–60%.

EFS_per_BICR

event-free survival

FIGURE 2 · Panel EFS_per_BICR

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel EFS_per_BICR 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Treatment and surgery summary in Japanese patients. The denominators for percentages were based on the number of patients randomized to each treatment group. AE, adverse event. a Included patient request and AEs unrelated to study treatment. b Surgery was abandoned in one patient in the perioperative nivolumab group. c one patient in the perioperative nivolumab group did not receive definitive surgery but received adjuvant treatment.
非 KM Figure
FIGURE 3FIGURE 3 (A) pCR and (B) MPR per BIPR in Japanese patients. BIPR, blinded independent pathological review; CI, confidence interval; MPR, major pathological response; NA, not available; OR, odds ratio; pCR, pathological complete response.
非 KM Figure